Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Rencofilstat Alone and With TDF in Healthy Volunteers and HBV Patients
NCT03596697Phase 1Completed
- Sponsor
- Hepion Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rencofilstat in Chronic Hepatitis B (CHB) (3 arms), sponsored by Hepion Pharmaceuticals. Primary endpoint: Number of healthy volunteers and patients with chronic HBV infection with treatment-related adverse events at 56 days. Started Jul 2019; status: completed.
02
Drugs
rencofilstat
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03596697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596697.